UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
Related reading
Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth
Why investors are chasing US biotechs with Chinese characteristics
Drugs developed in Asian nation are increasingly being used to seed US start-ups
UK urges pharma companies to invest after reaching drug pricing deal with US
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
US weight-loss biotech’s $600mn fund raise signals China’s role in drug trials
Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022